Is GEHC a Buy Now as Growth Improves but Execution Risks Persist?

GE HealthCare Technologies Inc. GEHC offers investors a mixed setup. Growth is improving in imaging and diagnostics, backlog remains elevated and valuation is below key benchmarks, but execution pressure in Patient Care Solutions and a heavier debt load limit the margin for error.

That balance argues for selectivity rather than chasing the recent operating momentum. The upside case depends on converting orders, scaling recurring businesses and offsetting inflation without allowing PCS weakness to dilute broader gains.

GEHC’s Valuation Offers a Potential Entry Point

GEHC trades at 14.27X forward 12-month earnings, below the Medical-Products sub-industry at 17.76X and its five-year median of 17.25X. That discount leaves room for rerating if earnings growth and margins improve.

Over the past five years, the stock has traded between 11.49X and 23.18X forward earnings. The current multiple therefore sits below the midpoint of its longer-term valuation range, but execution still matters.

Image Source: Zacks Investment Research

GE HealthCare Has Multiple Growth Engines

Advanced Imaging Solutions generated 5% organic revenue growth in the second quarter, while Pharmaceutical Diagnostics grew 14.6%. New imaging platforms, AI-enabled products, contrast-media demand and radiopharmaceutical adoption provide several growth avenues.

For industry context, Koninklijke Philips N.V. PHG is advancing a 2026-2028 health-technology plan, while Medtronic plc MDT continues introducing AI-enabled medical systems. Their innovation activity underscores the competitive intensity across medtech.

GEHC’s Recurring Revenue Mix Is Strengthening

Flyrcado, Vizamyl, contrast media, software and services can increase GEHC’s recurring-revenue exposure. Management targets more than $500 million in annual Flyrcado revenues and more than $200 million from Vizamyl by 2028.

Intelerad adds enterprise imaging software across hospital and outpatient settings, while AI-enabled software upgrades can also be offered through subscription models. A larger recurring mix could make growth less dependent on one-time equipment sales.

GE HealthCare’s Execution Risks Remain Significant

Patient Care Solutions remains the weakest segment. Second-quarter revenues fell 13.3%, segment EBIT was negative and operational fulfillment problems weighed on results, although first-half orders improved.

Inflation also remains a meaningful constraint. Management continues to expect about $250 million of 2026 inflation tied to memory chips, oil, freight and other components, increasing the importance of pricing, productivity and backlog conversion.

GEHC’s Balance Sheet Reduces Financial Flexibility

GE HealthCare ended the second quarter with $2.1 billion in cash and cash equivalents and $10.1 billion in debt after closing the $2.3 billion Intelerad acquisition in March.

Inventories rose to $2.48 billion at June 30 from $2.23 billion at year-end 2025. With second-quarter free cash flow at $68 million, integration discipline and working-capital execution are important to preserving capital-allocation flexibility.

GEHC’s Ratings Favor Selectivity Over Chasing Growth

GEHC has credible growth drivers and a valuation discount, but PCS weakness, inflation and leverage keep the investment case from being one-sided. The stock’s current setup favors a measured approach rather than an aggressive chase.

GEHC carries a Zacks Rank #2 (Buy). Its Value Score of B supports the valuation case, but the Growth Score of D, Momentum Score of F and VGM Score of C show that favorable near-term rank signals are not matched by uniformly strong style characteristics. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research